Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R

Lung Cancer. 2020 Jun:144:87-89. doi: 10.1016/j.lungcan.2020.03.018. Epub 2020 Mar 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Carcinoma, Non-Small-Cell Lung*
  • Carcinoma, Squamous Cell*
  • Humans
  • Lung Neoplasms* / drug therapy
  • Transcription Factors

Substances

  • Antibodies, Monoclonal, Humanized
  • PI3KCA protein, human
  • Transcription Factors
  • pembrolizumab